Formulation of HBs antigen in Montanide ISA266 shows superiority to commercial HBsAg vaccine in the induction of humoral immune responses

AIM: In the present study, a new formulation of HBsAg vaccine was developed and compared with a commercial peer. BACKGROUND: Vaccination of hepatitis B infection has been an unavoidable affair since the 1980s, though it has numerous limitations such as inefficacy in the induction of cellular immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Savoji, Mohammad Ali, Haghighat, Setareh, Mirzaee, Mina, Golkaran, Bahareh, Mirzaee, Rayhaneh, Esfandiari, Behzad, Mahdavi, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820835/
https://www.ncbi.nlm.nih.gov/pubmed/31749917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820835/
https://www.ncbi.nlm.nih.gov/pubmed/31749917

Ejemplares similares